title: Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept.
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Leteneux
authors.affiliation: Optum, Burlington, ON, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Haig
authors.affiliation: Optum, Uxbridge, UK.
authors.forename: W
authors.initials: W
authors.lastname: Xue
authors.affiliation: Novartis Healthcare Pvt. Ltd., Hyderabad, India.
authors.forename: S
authors.initials: S
authors.lastname: Bhattacharyya